Sign in Subscribe

meta-analysis

A collection of 17 issues

KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic

Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases

Skip to content The CRC Digest ▸ TREATMENT Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients

KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.

Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)

Meta-analysis examines timing of chemotherapy after colorectal cancer surgery

Skip to content The CRC Digest ◆ TRIAL DATA Meta-analysis examines timing of chemotherapy after colorectal cancer surgery A systematic review and meta-analysis evaluated the impact of early versus delayed postoperative chemotherapy on overall survival in colorectal cancer patients, aiming to guide clinical decisions on optimal chemotherapy timing. (J Gastrointest Cancer)

Endocrine side effects vary by immunotherapy regimen in CRC

Skip to content The CRC Digest Endocrine side effects vary by immunotherapy regimen in CRC A network meta-analysis of six randomized trials found that pembrolizumab and ICI plus tyrosine kinase inhibitor combinations significantly increased hypothyroidism risk, while hyperthyroidism was higher with ICI-TKI and ICI-chemotherapy-antiangiogenic regimens. (Frontiers in Immunology) This content

RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC A meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors,

First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J

Systematic review and meta-analysis quantifies sensitivity and specificity of fecal immunochemical testing and colonoscopy for colorectal cancer screening

Skip to content The CRC Digest ▪ SCREENING Systematic review and meta-analysis quantifies sensitivity and specificity of fecal immunochemical testing and colonoscopy for colorectal cancer screening Researchers analyzed multiple studies to estimate the accuracy of two major screening tests in asymptomatic average-risk adults. (Preventive Medicine Reports) This content is informational only

Meta-analysis projects rising early-onset CRC burden through 2030

Skip to content The CRC Digest Meta-analysis projects rising early-onset CRC burden through 2030 A systematic review and meta-analysis evaluated early-onset colorectal cancer (diagnosed under age 50) incidence and temporal trends from 1990 to 2021, identifying associated risk factors and projecting burden through 2030. (Cureus) This content is informational only